| Nov 21 |
Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera
|
| Nov 21 |
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
|
| Nov 5 |
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
|
| Nov 4 |
Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab
|
| Nov 2 |
Zymeworks Third Quarter 2024 Earnings: Revenues Disappoint
|
| Nov 1 |
Zymeworks Q4 2024 Earnings Preview
|
| Nov 1 |
Zymeworks drops as Wells Fargo cuts on valuation
|
| Nov 1 |
Zymeworks Inc. (NASDAQ:ZYME) Analysts Are Reducing Their Forecasts For Next Year
|
| Nov 1 |
Zymeworks Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Nov 1 |
Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript
|
